Vastarel
formulated to support patients with angina to address underlying metabolic myocardial ischemia.
Strengths: 20mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Vastarel MR
- Therapeutic class
Anti-anginal agent
- Pharmacological class
Piperazine derivative
- Contraindications
hypersensitivity to trimetazidine; parkinson's disease; severe renal impairment
- Precautions and warnings
monitor for movement disorders; discontinue if neurological symptoms occur
- Minor side effects
dizziness; headache; abdominal pain; diarrhoea
- Moderate side effects
asthenia; rash; pruritus
- Dosage forms
Modified-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Servier
- Onset Time
1–2 weeks
- Duration
continuous
- Storage instructions
Store below 30°C.
- Age restrictions
Not recommended for children.
- Pregnancy and breastfeeding
Pregnancy: Avoid in pregnancy. Breastfeeding: Avoid.
Serious side effects
parkinsonism — requires immediate medical attention; tremor — requires immediate medical attention
Patient summary
formulated to support patients with angina to address underlying metabolic myocardial ischemia.
Mechanism of action
Trimetazidine acts as a metabolic agent that shifts myocardial metabolism from fatty acid oxidation to glucose oxidation, which is more oxygen-efficient.
Vastarel
formulated to support patients with angina to address underlying metabolic myocardial ischemia.
Editorial Notes
- Active ingredient(s): Trimetazidine
- Listed indication(s): Stable Angina Pectoris
Available option
- 90 capsules - 20 mg1557-20-mg-18103